Related content

IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy

By                    

International Journal of Oncology, Vol. 41, Iss. 4, 2012-01 ,pp. : 1325-1336

Spandidos Publications

Access to resources Recommend Favorite

Lenalidomide treatment for patients with myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure

By Prebet Thomas   Charbonnier Aude   Gelsi-Boyer Véronique   Mozziconacci Marie Joelle   Blaise Didier   Vey Norbert  

Leukemia and Lymphoma, Vol. 54, Iss. 7, 2013-07 ,pp. : 1538-1540

Informa Healthcare

Access to resources Recommend Favorite

Overall and progression-free survival and visual and endocrine outcomes for patients with parasellar lesions treated with intensity-modulated stereotactic radiosurgery

By Jensen Randy   Jensen Peter   Shrieve Annabelle   Hazard Lisa   Shrieve Dennis  

Journal of Neuro-Oncology, Vol. 98, Iss. 2, 2010-06 ,pp. : 221-231

Springer Publishing Company

Access to resources Recommend Favorite

Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis

By Takano Masashi   Sugiyama Toru   Yaegashi Nobuo   Suzuki Mitsuaki   Tsuda Hiroshi   Sagae Satoru   Udagawa Yasuhiro   Kuzuya Kazuo   Kigawa Junzo   Takeuchi Satoshi   Tsuda Hitoshi   Moriya Takuya   Kikuchi Yoshihiro  

International Journal of Clinical Oncology, Vol. 12, Iss. 4, 2007-08 ,pp. : 256-260

Springer Publishing Company

Access to resources Recommend Favorite

The palliative prognostic score and survival in patients with advanced solid tumors receiving chemotherapy

By Tassinari Davide  

Supportive Care in Cancer, Vol. 16, Iss. 4, 2008-04 ,pp. : 359-370

Springer Publishing Company

Access to resources Recommend Favorite